# A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

> **NCT05975060** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novavax** · enrollment: 660 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** XBB.1.5 Vaccine (Booster)
- **BIOLOGICAL:** XBB.1.5 Vaccine (single dose)

## Key facts

- **NCT ID:** NCT05975060
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-07
- **Primary completion:** 2023-11-15
- **Final completion:** 2024-05-20
- **Target enrollment:** 660 (ACTUAL)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05975060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05975060, "A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05975060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*